Ph 1a data of TOS-358 in heavily pretreated patients with PI3Kα-mutant metastatic breast cancer and other solid tumors presented March 24, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. March 10, 2026
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio March 10, 2026
NMPA approves IND application for HLX97 for the treatment of advanced or metastatic solid tumors March 10, 2026
FDA approves IND application for Ph 1 trial of KGX105 monotherapy in locally advanced or metastatic solid tumors March 10, 2026
FDA approves IND application for KST-0651 for Ph 1 trial in Advanced Solid Tumors including pancreatic cancer, CRC, NSCLC, and others March 10, 2026
FDA approves IND application for GNTbm-38 for Ph 1 trial in Advanced Solid Tumors and R/R PTCL March 10, 2026
IND Application filed for ML-016 for Advanced Solid Tumors with Lung and/or Liver Mets March 10, 2026
Cellares and University of Wisconsin School of Medicine and Public Health Expand Partnership to Clinical Manufacturing of CRISPR-Edited CAR-T for Solid Tumors February 25, 2026
Sift Biosciences Announces Oversubscribed $3.7M Pre-seed Financing to Advance Next-gen T-cell Immunotherapy Platform February 25, 2026
MHRA and REC approved CTA for Ph 1 ZIMA-101 trial of ZI-MA4-1 in patients with advanced solid cancers February 25, 2026
FDA Clears IND Application for CS2009 (PD-1/VEGF/CTLA-4) to Advance into Ph 2 Clinical Trial February 25, 2026
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors February 17, 2026
CARsgen Signs Strategic Cooperation Agreements to Expand CAR-T Commercial Manufacturing Base in China February 17, 2026
First Patient Enrolled in Global Ph 1 Trial of AN9025 for Solid Tumors Harboring RAS Mutations February 17, 2026
FDA cleared IND application for NPX372 in B7-H7–expressing solid tumors, including lung adenocarcinoma, RCC, and pancreatic adenocarcinoma February 17, 2026
FDA clears IND application for Ph 1 study of GTB-5550 TriKE for Solid Tumors Expressing B7-H3 February 9, 2026
FDA clears IND application for Ph 1 study of N17350 in patients with advanced solid tumors February 9, 2026
